Testing a new medication for relapsing multiple sclerosis in young people

Plain-English translation of NCT07161258 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called to see how it works in children and adolescents with relapsing multiple sclerosis (a type of MS where symptoms come and go). Researchers want to understand how the medication moves through your body, how it affects your immune system, and whether it is safe and well-tolerated in young patients. The study will last several months, and you may have the option to continue taking the medication after the initial testing period if you and your doctor decide that's right for you.

Most MS medications have only been tested in adults, so doctors don't have enough information about how safe and effective these treatments are for children and teenagers. This medication has shown promise in older patients, and this study will help researchers understand whether it can help young people with relapsing MS in a safe way.

Do you qualify?

You likely qualify if…

you are between 10 and 17 years old
you have been diagnosed with relapsing multiple sclerosis using standard diagnostic criteria
you have had at least one MS relapse in the past year, or two relapses in the past two years, or evidence of active disease on recent MRI scans
your disability level is relatively mild to moderate (EDSS score between 0 and 5.5)
you are up to date on all recommended childhood vaccinations

You likely don't qualify if…

you have primary progressive or non-active secondary progressive multiple sclerosis
you have a serious infection, history of cancer, bleeding disorder, or other significant medical or psychiatric illness
you are currently taking certain MS medications or immunosuppressants that might interfere with this study
you have liver problems, abnormal blood counts, or are allergic to any ingredient in fenebrutinib
you are at risk for suicide or have had recent thoughts of harming yourself

What participation looks like

You would take by mouth as a tablet during an initial dose exploration period lasting several months. During this time, you'll have regular visits with the research team to have blood tests, MRI scans, and checkups to see how your body responds to the medication and whether you're experiencing any side effects. If all goes well and you want to continue, you may be able to keep taking the medication in an optional extension period. The study is being conducted at specialized medical centers, and your parent or guardian will be involved throughout.

AI-generated summary from trial data · Jul 12, 2026 · Not medical advice

Trial locations(17 sites)

Argentina

INECO Neurociencias Orono, Rosario, Santa Fe Province

Sanatorio del Sur S.A., San Miguel de Tucumán

Brazil

L2IP ?Instituto de Pesquisas Clínicas Ltda., Brasília, Federal District

Instituto de Neurologia de Curitiba - Hospital Ecoville, Curitiba, Paraná

Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR, Porto Alegre, Rio Grande do Sul